...
首页> 外文期刊>Digestive Diseases and Sciences >Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: Evidence from a US national survey
【24h】

Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: Evidence from a US national survey

机译:直接医疗保险公司和炎症性肠病的自付费用:来自美国国家调查的证据

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Crohn's disease (CD) and ulcerative colitis (UC) are chronic, debilitating conditions that can have important economic and clinical implications. Aim: To quantify individual and national estimates of the health care and patient out-of-pocket (OOP) costs of CD and UC. Methods: In a retrospective study using 1996 to 2009 data from the Medical Expenditure Panel Survey, individuals' self-reported health conditions were mapped to International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes. Individuals with a code of 555.x (CD) or 556.x (UC) were identified. Health care services and costs included prescriptions and inpatient, outpatient, emergency room, office, and home health services. OOP costs were the portion of individuals' total payments for health care services. Results: There were 358 individuals with CD (mean age 49.0 years; 55 % female), 198 individuals with UC (mean age 47.1 years; 64 % female), and 206,993 individuals without inflammatory bowel disease (IBD) (mean age 48.2 years; 58 % female). Annual per capita health insurer and OOP costs for individuals with CD were greater than those without IBD ($9,526 versus $3,781, p < 0.001 and $1,603 versus $866, p < 0.001, respectively). Health insurer and OOP costs were greater for UC compared with those without IBD ($6,443 versus $3,781, p < 0.001 and $1,263 versus $866, p < 0.001, respectively). US national aggregate annual estimates of health insurer, OOP, and total direct costs secondary to CD are $2.04 billion, $0.26 billion, and $2.29 billion, respectively. Aggregate health insurer, OOP, and total direct costs attributable to UC are $0.53 billion, $0.07 billion, and $0.61 billion, respectively. Conclusions: The direct costs associated with CD and UC are substantial. The extent to which appropriate diagnosis and treatment reduces the total health care costs for individuals with CD or UC should be examined.
机译:背景:克罗恩病(CD)和溃疡性结肠炎(UC)是慢性衰弱性疾病,可能具有重要的经济和临床意义。目的:量化个人和国家对CD和UC的医疗保健和患者自付费用(OOP)的估计。方法:在一项回顾性研究中,使用来自医疗支出小组调查的1996年至2009年的数据,将个人自我报告的健康状况映射到《国际疾病分类》,《第九修订版》,《临床修改》诊断代码。确定代码为555.x(CD)或556.x(UC)的个人。卫生保健服务和费用包括处方和住院,门诊,急诊室,办公室和家庭卫生服务。 OOP成本是个人支付的医疗服务总费用的一部分。结果:358例CD患者(平均年龄49.0岁;女性55%),198例UC患者(平均年龄47.1岁; 64%女性)和206,993例无炎症性肠病(IBD)的患者(平均年龄48.2岁;平均年龄48.2岁)。 58%的女性)。患有CD的人每年的人均健康保险和OOP费用要高于没有IBD的人(分别为9,526美元对3,781美元,p <0.001和1,603美元对866美元,p <0.001)。与没有IBD的UC相比,UC的医疗保险和OOP费用更高(分别为6,443美元对3,781美元,p <0.001和1,263美元对866美元,p <0.001)。美国国家对健康保险公司,OOP和CD产生的直接费用的年度总估算分别为20.4亿美元,2.6亿美元和22.9亿美元。总体医疗保险公司,OOP和可归因于UC的总直接成本分别为5.3亿美元,0.7亿美元和6.1亿美元。结论:与CD和UC相关的直接成本是巨大的。应该检查适当的诊断和治疗在多大程度上降低了CD或UC患者的总体医疗保健成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号